Stifel Nicolaus Boosts Spyre Therapeutics (NASDAQ:SYRE) Price Target to $54.00

Spyre Therapeutics (NASDAQ:SYRE) had its target price hoisted by Stifel Nicolaus from $36.00 to $54.00 in a research note issued to investors on Tuesday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other analysts have also commented on SYRE. TD Cowen started coverage on Spyre Therapeutics in a report on Wednesday, November 29th. They issued an outperform rating on the stock. Lifesci Capital reaffirmed an outperform rating on shares of Spyre Therapeutics in a research note on Monday, December 4th. Guggenheim initiated coverage on Spyre Therapeutics in a research note on Monday, December 11th. They issued a buy rating and a $44.00 price target on the stock. BTIG Research initiated coverage on Spyre Therapeutics in a research note on Wednesday, December 20th. They issued a buy rating and a $32.00 price target on the stock. Finally, Jefferies Financial Group initiated coverage on Spyre Therapeutics in a research note on Monday, December 11th. They issued a buy rating and a $31.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Spyre Therapeutics presently has an average rating of Buy and an average price target of $39.20.

Spyre Therapeutics Stock Performance

Shares of SYRE opened at $37.93 on Tuesday. Spyre Therapeutics has a 12 month low of $2.66 and a 12 month high of $47.97. The firm has a 50 day simple moving average of $30.51. The firm has a market capitalization of $153.62 million, a price-to-earnings ratio of -0.50 and a beta of 2.85.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($2.28) EPS for the quarter, missing the consensus estimate of ($0.48) by ($1.80). On average, analysts anticipate that Spyre Therapeutics will post -2.52 earnings per share for the current fiscal year.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).